

Remarks

Applicant hereby elects without traverse to prosecute in this application the subject matter of Group I, claims 1- 6, 8-11, 32, 33 and 39 drawn to an isolated nucleic acid, probe, vector and host cell. Applicants reserve the right to prosecute any subject matter not examined here in one or more divisional application(s).

Regarding the additional restriction requirement for a sequence election, Applicant hereby elects with traverse to prosecute in this application the sequence of SEQ ID NO: 1.

Regarding the traversal Applicant respectfully points out that the SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 11, 4796 and 4800 which are referenced in elected Group I (claims 1-6, 8-11, 32, 33 & 39) are all closely related. Human testis expressed patched like protein of the subject invention included two isoforms, HTPL-L the long form and HTPL-S the short form. SEQ ID NO: 1 is the full length HTPL-L cDNA. SEQ ID NO: 2 is the open reading frame portion of the same HTPL-L cDNA. SEQ ID NO: 3 is the amino acid sequence of the full length HTPL-L protein encoded by the nucleotide sequence of NO: 1. Finally, SEQ ID NOS: 7 & 11 are portions of the nucleotide sequence of NO: 1.

Similarly, SEQ ID NO: 4 is the full length HTPL-S cDNA. SEQ ID NO: 5 is the open reading frame portion of the same HTPL-S cDNA. SEQ ID NO: 6 is the amino acid sequence of the full length HTPL-S protein encoded by the nucleotide sequence of NO: 4

and SEQ ID NOS: 4796 & 4800 are portions of the nucleotide sequence of NO: 4. In view of the above, Applicant submits that although it may now be customary for Group 1631 to limit examination to one sequence, it should not constitute an undue burden, in fact, for the Examiner to consider all ten of the closely related sequences of Group I together.

Sequence Compliance


Applicant has added new sequences numbered 4805 through 4809 to incorporate the sequences identified in Figure 1B. Per the Examiner's instructions, Applicant has amended the Brief Description of the Drawings section in the specification to insert the corresponding sequence identification numbers. Due to the need to list the additional sequences, Applicant submits herewith a new CD-ROM containing the revised "Sequence Listing" and computer readable form "Sequence Listing" copies along with the required statements under 37 CFR § 1.821 (f) and (g). Applicant respectfully requests that the revised "Sequence Listing" submitted herewith replace the original "Sequence Listing" as filed.

Applicant has additionally revised Figure 1B to insert the corresponding sequence identification numbers. Appended hereto is a copy of Figure 1B labeled "Annotated Sheet Showing Changes" whereon the sequence identification numbers are inserted in red ink. Additionally, appended hereto is a revised Figure 1B labeled "Replacement Sheet"

whereon the sequence identification numbers are properly printed. Applicant respectfully requests that the Examiner accept the changes to the drawing figure and enter same.

Early and favorable action is earnestly solicited.

Respectfully submitted




Stephen G. Ryan
Registration No.: 39,015
Attorney for Applicants

Amersham Biosciences Corp
800 Centennial Avenue
P. O. Box 1327
Piscataway, New Jersey 08855-1327

Tel: (732) 457-8071
Fax: (732) 457-8463

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on July 30, 2003.

Signature: 

Name: Melissa Leck